DEA Plays Chemical Whack-A-Mole With Designer Drug CUMYL-PEGACLONE
Published Date: 12/11/2025
Proposed Rule
Summary
The Drug Enforcement Administration wants to make the temporary ban on CUMYL-PEGACLONE permanent by placing it in Schedule I, meaning it’s considered very risky and illegal to handle without special permission. This affects anyone who makes, sells, studies, or possesses this substance. Comments and hearing requests are open until January 12, 2026, so speak up before then!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Unauthorized handling may bring penalties
The proposal says any activity with CUMYL-PEGACLONE that is not authorized under the Controlled Substances Act would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions under Schedule I rules.
CUMYL-PEGACLONE moved to Schedule I
The Drug Enforcement Administration proposes to permanently place CUMYL-PEGACLONE (also called SGT-151) in Schedule I, making permanent the temporary controls first ordered on December 12, 2023. If finalized, anyone who manufactures, distributes, imports, exports, researches, or possesses this substance would be subject to the regulatory controls for Schedule I substances; comments are due January 12, 2026.
Required registrations, security, and controls
If finalized, anyone handling CUMYL-PEGACLONE must follow Schedule I requirements: register with DEA, meet Schedule I security rules, use specified labeling and packaging, comply with manufacturing quotas, keep initial and biennial inventories, maintain records and reports, use required order forms, and follow import/export controls.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-22490 — Guidance on Response Programs for Unauthorized Access to Member Information and Member Notice
The National Credit Union Administration (NCUA) is updating how it shares rules about handling unauthorized access to member info. Instead of keeping detailed guidance in the official rulebook, they’ll publish it separately to make updates easier and reduce confusion for credit unions. This change affects federally insured credit unions and invites public comments until February 9, 2026, with no new costs involved.
Next: 2025-22499 — Establishment of Class E Airspace; Providence Seaside Hospital Heliport, Seaside, OR
The FAA is planning to create new Class E airspace around Providence Seaside Hospital Heliport in Seaside, Oregon, starting 700 feet above the ground. This change helps pilots safely use GPS-based flight paths for takeoffs and landings, making helicopter flights smoother and safer. If you want to share your thoughts, make sure to comment by January 26, 2026—no costs or fees involved!